Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., filed to seek approval for marketing authorization for fexapotide triflutate in five European countries: the Netherlands, the U.K., Germany, France and Spain. That first filing is for treating the symptoms of benign prostatic hyperplasia, or prostate enlargement. Fexapotide has been in development by Nymox for 15 years. (See BioWorld Today, Oct. 12, 2016.)